Intravitreal Anti-VEGF Pharmacotherapy and Kidney Failure: Protecting Vision with an Eye on Renal Safety
-
Published:2024-08
Issue:8
Volume:8
Page:731-732
-
ISSN:2468-6530
-
Container-title:Ophthalmology Retina
-
language:en
-
Short-container-title:Ophthalmology Retina
Reference10 articles.
1. Similar risk of kidney failure among patients with blinding diseases who receive ranibizumab, aflibercept, and bevacizumab: an Observational Health Data Sciences and Informatics Network Study;Cai;Ophthalmol Retina,2024
2. VEGF inhibition, hypertension, and renal toxicity;Hayman;Curr Oncol Rep,2012
3. Systemic pharmacokinetics and pharmacodynamics of intravitreal aflibercept, bevacizumab, and ranibizumab;Avery;Retina,2017
4. Plasma vascular endothelial growth factor concentrations after intravitreous anti-vascular endothelial growth factor therapy for diabetic macular edema;Jampol;Ophthalmology,2018
5. Review of intravitreal VEGF inhibitor toxicity and report of collapsing FSGS with TMA in a patient with age-related macular degeneration;Phadke;Clin Kidney J,2021